Safety of Icotrokinra Through 1 Year for the Treatment of Moderate-to-Severe Plaque Psoriasis and Psoriasis Affecting High-Impact Sites: Pooled Results Across the ICONIC-LEAD, ICONIC-TOTAL, and ICONIC-ADVANCE 1 and 2 Phase 3 Trials
Authors: Mark G Lebwohl, Melinda Gooderham, Richard B Warren, Lawrence F Eichenfield, Jessica H Rubens, Tracy Cardillo, Christopher Russo, Cynthia M C DeKlotz, Megan Miller-Kassamali, Luis Anaya Velarde, Ming-Chun Hsu, Shu Li, Ya-Wen Yang, Sarah Ofori, Robert Bissonnette, Jennifer Soung, Adelaide A Hebert, Linda Stein Gold Read more on pubmed
EP262, an MRGPRX2 Antagonist for the Treatment of Atopic Dermatitis: Results From the Phase 2 Randomized EASE Study
Authors: Dehn, S., Cooper, D., Weyer, C., Ferguson, B., Srinivasan, S., Saint-Cyr Proulx, E., & Bissonnette, R. Read more on pubmed
Placebo Response in Randomised Controlled Trials of Systemic Therapies for Cutaneous Lupus Erythematosus: A Systematic Review and Meta-Analysis
Authors: LĂ©garĂ©, S., Lin, S., Vahey, S., Ovalles-Bonilla, J. G., D’Angelo, P., Jankicevic, J., & Bissonnette, R. Read more on pubmed
Durability of Response to Icotrokinra in Adults With Moderate-to-Severe Plaque Psoriasis: One-Year Results From the Phase 3, Placebo- and Active Comparator-Controlled ICONIC-ADVANCE 1 & ICONIC-ADVANCE 2 Trials
Authors: Linda Stein Gold, April W Armstrong, Jennifer Soung, Ronald B Vender, Ălvaro GonzĂĄlez Cantero, Matthias Hoffmann, Scott T Guenthner, H Chih-Ho Hong, Dedee F Murrell, Eingun James Song, Leon Kircik, Matthias Augustin, Maxwell Sauder, Sascha Gerdes, Ofelia Reyes-Servin, Bassey Effiom Edem, Jennifer Campbell, Kellen Cresswell, Lea Kephart, Shu Li, Ya-Wen Yang, Robert Bissonnette Read […]
Ruxolitinib Cream Demonstrated Rapid Reductions in Itch and Atopic Dermatitis Signs That Correlated With Biomarkers
Authors: Bissonnette, R., Saint-Cyr Proulx, E., Correa da Rosa, J., Estrada, Y., Ren, H., Nawaz, H., Halden, P., Stefani-Hunyady, D., Popovic, K., Volkova, A., Smith, S. H., & Guttman-Yassky, E. Read more on pubmed
What Placebo Response Data in Atopic Dermatitis Trials are Actually Telling Us
Placebo response, which has emerged as an important determinant of interpretability and success in atopic dermatitis (AD) clinical trials, is frequently a predictable consequence of conducting high-quality clinical studies in a disease characterized by inherent variability over time. Modern AD programs increasingly acknowledge placebo response as a structural feature rather than an anomaly. Adaptive designs, […]
Placebo Response in Clinical Trials for Hidradenitis Suppurativa
Potential contributors to placebo rates in hidradenitis suppurativa (HS) clinical trials include underlying disease variability, the relative lack of efficacy of current therapies, and the requirement for rescue therapy and/or concomitant medications. More specifically, the contributors to placebo response lie in the difficulty in evaluating disease severity in HS, lack of non-physician or patient-assessed objective measures […]
Characterizing the Burden of Hand Dermatitis in Canada: A Cross-Sectional Survey of Disease Impact
Authors: Cresswell-Melville, A., Mehta, S., Metko, D., Bissonnette, R., & Molin, S. Read more on pubmed
Reflections on SID 2026: Advances in Dermatology Research
Indero exhibited at the 83rd annual meeting of the Society for Investigative Dermatology (SID) May 13-16, 2026 in Chicago. Our Chief Medical & Scientific Officer, Jasmina Jankicevic, co-chaired the Future Leaders Retreat at SID 2026, and was on the Education Committee that organized this yearâs SID. Among other Indero employees at SID 2026, was Julie Basque, Senior Clinical Scientist, who reflects here on her experience. SID 2026 was a great snapshot of how quickly […]
Durability of response to icotrokinra for high-impact site psoriasis: 1-year ICONIC-TOTAL findings
Authors: Warren, R. B., Gooderham, M., Lain, E., Bissonnette, R., Huang, Y. H., Ringuet, J., Hoffmann, M., Pinter, A., Merola, J. F., Rubens, J. H., Fan, D., Hsu, M. C., Li, S., Yang, Y. W., DeKlotz, C. M. C., & Song, E. J. Read more on pubmed
